Three Korean KOSDAQ Firms Launch Capital Increases to Resolve Delisting Risks

Three KOSDAQ-listed companies — Telcon RF Pharmaceutical, KPM Tech, and Newon — initiated sequential paid-in capital increases on July 7, 2026, according to Chosun Biz. The move aims to resolve delisting risks facing the companies. The capital injection begins with a 5 billion won investment from the companies' real owner, addressing regulatory concerns while dissolving the circular shareholding structure that previously connected the three firms.

Real Owner Invests 5 Billion Won to Initiate Capital Restructuring

The real owner contributed personal funds to launch the sequential capital increases across the three companies. The structure of the capital injections minimizes cash outflow outside the group while addressing delisting concerns. The three companies were previously connected through circular shareholding arrangements, which are being unwound through this process.

FAQ

What did Telcon RF Pharmaceutical, KPM Tech, and Newon announce on July 7, 2026?

The three KOSDAQ-listed companies announced sequential paid-in capital increases starting with a 5 billion won investment from their real owner, according to Chosun Biz.

Why are these three Korean companies conducting capital increases?

The companies are conducting the capital increases to resolve delisting risks and dissolve the circular shareholding structure that previously connected them.